•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Lian SGP Holding Pte. Ltd., a subsidiary of Livzon Pharmaceutical Group (China), said it has completed the purchase of more than 104.5 million shares of Imexpharm Joint Stock Company (IMP), equivalent to 67.87% of Imexpharm’s charter capital. Following the transaction, the Chinese group becomes the parent company of Vietnam’s leading pharmaceutical firm.
The acquisition was carried out under Lian SGP’s public tender offer announced in mid-January 2026. At the time, Lian SGP registered to acquire more than 120 million IMP shares, representing 77.94% of charter capital, at a bid price of 57,400 dong per share. Based on the offer price, the transaction value was approximately 6,000 billion dong.
IMP shares were trading near their six-month low at around 46,600 dong per share, roughly 19% below the tender offer price. The company’s market capitalization was reported at nearly 7,200 billion dong.
Livzon is a major Chinese pharmaceutical group founded in 1985, with registered capital of over 935 million yuan. The group operates across research and development, production of pharmaceuticals, modern medicines, traditional Chinese medicine, and active ingredients, and has a presence in more than 30 countries, including the US, EU, Korea, Japan, and Southeast Asia.
According to the available information, Livzon’s plan to acquire Imexpharm was announced toward the end of May 2025. The proposed buyout framework involved acquiring shares held by three major shareholders, including SK Investment, CTCP Đầu tư Bình Minh Kim, and CTCP Đầu tư KBA.
Imexpharm is among Vietnam’s leading domestic pharmaceutical companies, with plants compliant with EU-GMP standards. The company currently owns 12 EU-GMP production lines across three major plant clusters.
In Vietnam’s pharmaceutical sector, most firms have WHO-GMP, while EU-GMP (or equivalent) facilities account for just over 10% of the industry. This positioning supports Imexpharm’s role in hospital tenders and in producing higher-quality medicines to replace imports.
At Imexpharm’s 2026 annual general meeting, CEO Ms. Tran Thi Dao said Livzon has strong R&D capabilities, including injectable medicines approved by the US FDA. She also noted that Livzon is among the top 25 Chinese pharmaceutical companies.
Looking ahead, Livzon said it will maintain Imexpharm’s stable production-and-business strategy while expanding the portfolio of high-tech products on EU-GMP lines. Imexpharm leadership stated that the strategic investor’s involvement is expected to enhance R&D capabilities and provide access to advanced technologies.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
